Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Clovis

SWITCHED ONcology Patient Experience Focus Group Full Discussion

On 22nd February we held our patient experience focus group, which brought together patients, doctors and industry advocates to discuss the changing landscape and challenges facing cancer care today. In...

Havas Lynx

SWITCHED ONcology Patient Experience Focus Group Highlights

On 22nd February we held our patient experience focus group, which brought together patients, doctors and industry advocates to discuss the changing landscape and challenges facing cancer care today. "We...

Havas Lynx

SWITCHED ONcology

We bring together the experts. The patients. The scientists. The technologists. The creatives. We unite powerful insights to make science mean something real. We are stronger together. We are Switched...

Havas Lynx

18 SWITCHED ONcology: The Big Communication

Matching unprecedented clinical advances in immuno-oncology with transformative communication

Havas Lynx

Bristol-Myers Squibb (BMS) building

BMS presses go on Nektar combo pivotal trials, despite data debate

The data isn’t mature enough to give an accurate ORR reading, says companies

- PMLiVE

Improving childhood cancer survival rates in developing countries

IntroductionOne of the remarkable success stories in cancer care has been the increase in the long-term survival of children with leukaemia and solid tumours from almost nil to 75-80% cure...

- PMLiVE

Immuno-oncology at ASCO: survival data, combinations and new indications

The abstracts reveal heaps of strong contenders in the NSCLC category

- PMLiVE

Cancer in The Information Age: are we illuminated or inundated?

Is cancer becoming too complicated, too interconnected, for human understanding alone?

- PMLiVE

Morning brief: Herzuma launched in Europe, rare disease status for Orchard candidate and more

A rapid round-up of pharma, biotech and healthcare news

Bristol-Myers Squibb (BMS) building

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

Suspends enrolment in BMS-986205 trials for NSCLC and head and neck cancer

- PMLiVE

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

AstraZeneca, Roche and Gilead among companies one step closer to approval

Bristol-Myers Squibb (BMS) building

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

Data shows the combo can improve survival compared to Pfizer’s Sutent

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links